CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2578 Two doses of placebo at the schedule of day 0,28 Wiki 1.00
drug2571 Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki 1.00
drug2575 Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D007410 Intestinal Diseases NIH 1.00
D015212 Inflammatory Bowel Diseases NIH 0.50
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002242 Abnormal intestine morphology HPO 1.00
HP:0002037 Inflammation of the large intestine HPO 0.50

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged ≥60 Years

This study is a randomized, double-blinded, and placebo controlled phase 1&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults aged≥60 years.

NCT04383574 COVID-19 Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Other: Two doses of placebo at the schedule of day 0,28

Primary Outcomes

Description: Incidence of adverse reactions after each dose vaccination

Measure: Safety index-incidence of adverse reactions

Time: Day 0-28 after each dose vaccination

Description: Neutralizing antibody assay will be performed using the micro-neutralization method. Seroconversion will be defined as a change from seronegative (<1:8) to seropositive (≥1:8), or ≥4 fold increase from baseline.

Measure: Immunogenicity index-seroconversion rates of neutralizing antibody

Time: The 30th day after the second dose vaccination

Secondary Outcomes

Description: SAE will be collected throughout the clinical trial

Measure: Safety index-incidence of serious adverse events

Time: From the beginning of the vaccination to 12 months after the second dose vaccination

Description: Neutralizing antibody assay will be performed using the micro-neutralization method, and subjects with a antibody titer ≥1:8 will defined as seropositive.

Measure: Immunogenicity index-seropositive rates of neutralizing antibody

Time: The 30th day and the 12 month after the second dose vaccination

Description: Neutralizing antibody assay will be performed using the micro-neutralization method

Measure: Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody

Time: The 30th day and the 12 month after the second dose vaccination

Description: Neutralizing antibody assay will be performed using the micro-neutralization method. Ratio of post-vaccination titer divided by baseline titer will be calculated.

Measure: Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody

Time: The 30th day after the second dose vaccination


No related HPO nodes (Using clinical trials)